AGLE
Aeglea Biotherapeutics, Inc.
Chart
Stats
Earnings
News
Splits
Dividends
Earnings
| Actual EPS |
|---|
| Consensus EPS |
| Estimated EPS |
| Number of Estimates |
| EPS Surprise |
Stats
Summary
Aeglea Biotherapeutics, Inc. operates as a clinical-stage biotechnology company, which develops next-generation human enzyme therapeutics as disruptive solutions for rare and other high-burden diseases. Its product pegzilarginase, is in a Phase 3 pivotal trial for the treatment of Arginase 1 Deficiency. The company was founded by George Georgiou and David G. Lowe in December 2013 and is headquartered in Austin, TX.
Market Cap: 136 Million
Primary Exchange: NASDAQ
Website: http://www.aegleabio.com
Shares Outstanding: 29.1 Million
Float: 25.2 Million
Dividend: (%)
Beta: 1.53952220274056
Sector: Health Technology
Industry: Pharmaceuticals: Major
Ethical Flags
Longest drawdown: 1531 trading days
From: 2016-04-08 To: 2020-03-30
Lowest Point:
| Ex-Date | Payment Date | Record Date | Declared Date | Amount | Flag | Dividend Type | Qualified | Indicated |
|---|
| Ex-Date | Declared Date | Record Date | Payment Date | Ratio | To Factor | For Factor |
|---|